Warfarin reversal with prothrombin complex concentrate confers better antifibrinolytic activity compared with recombinant activated factor VII.
Taketomi
Taro
T
Szlam
Fania
F
Levy
Jerrold H
JH
Tanaka
Kenichi A
KA
D000925:Anticoagulants / Q000009:adverse effects*; D001779:Blood Coagulation Factors / Q000494:pharmacology*; D004347:Drug Interactions; D015942:Factor VIIa / Q000494:pharmacology*; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D010949:Plasma / Q000502:physiology; D011994:Recombinant Proteins / Q000494:pharmacology; D013916:Thrombelastography; D013917:Thrombin / Q000378:metabolism; D014859:Warfarin / Q000009:adverse effects*
D000925:Anticoagulants; D001779:Blood Coagulation Factors; D011994:Recombinant Proteins; C025667:prothrombin complex concentrates; D014859:Warfarin; C103587:recombinant FVIIa; D015942:Factor VIIa; D013917:Thrombin